Wall Street analysts expect AveXis (NASDAQ:AVXS) to announce earnings of ($1.95) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for AveXis’ earnings, with the highest EPS estimate coming in at ($1.28) and the lowest estimate coming in at ($2.71). AveXis posted earnings per share of ($1.07) in the same quarter last year, which would indicate a negative year-over-year growth rate of 82.2%. The company is scheduled to issue its next earnings report on Thursday, May 10th.
On average, analysts expect that AveXis will report full-year earnings of ($7.63) per share for the current financial year, with EPS estimates ranging from ($11.79) to ($5.62). For the next fiscal year, analysts anticipate that the company will post earnings of ($7.22) per share, with EPS estimates ranging from ($12.21) to ($1.85). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for AveXis.
AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($2.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.91).
Several brokerages recently weighed in on AVXS. ValuEngine upgraded AveXis from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. BidaskClub cut AveXis from a “buy” rating to a “hold” rating in a report on Monday, April 2nd. Canaccord Genuity set a $110.00 target price on AveXis and gave the company a “hold” rating in a report on Friday, January 5th. Mizuho set a $147.00 target price on AveXis and gave the company a “buy” rating in a report on Wednesday, March 14th. Finally, Morgan Stanley set a $120.00 target price on AveXis and gave the company a “buy” rating in a report on Friday, January 5th. Three analysts have rated the stock with a sell rating, four have given a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $123.90.
In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $118.07, for a total value of $1,771,050.00. Following the completion of the sale, the insider now owns 1,792,147 shares in the company, valued at approximately $211,598,796.29. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Sean P. Nolan sold 10,000 shares of the stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $129.47, for a total value of $1,294,700.00. Following the completion of the transaction, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $1,294,700. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,780 shares of company stock valued at $8,341,178. Company insiders own 18.60% of the company’s stock.
Several large investors have recently made changes to their positions in AVXS. Perceptive Advisors LLC raised its position in shares of AveXis by 147.5% in the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock worth $64,923,000 after acquiring an additional 400,000 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock worth $99,363,000 after acquiring an additional 352,456 shares in the last quarter. Carillon Tower Advisers Inc. bought a new position in shares of AveXis in the 4th quarter worth approximately $24,033,000. Eagle Asset Management Inc. raised its position in shares of AveXis by 123.4% in the 4th quarter. Eagle Asset Management Inc. now owns 354,154 shares of the company’s stock worth $39,274,000 after acquiring an additional 195,626 shares in the last quarter. Finally, Deutsche Bank AG raised its position in shares of AveXis by 42.7% in the 4th quarter. Deutsche Bank AG now owns 303,901 shares of the company’s stock worth $33,630,000 after acquiring an additional 90,934 shares in the last quarter. 82.43% of the stock is owned by hedge funds and other institutional investors.
AVXS stock traded down $3.69 during trading on Wednesday, hitting $115.91. 308,255 shares of the company traded hands, compared to its average volume of 329,955. AveXis has a 1 year low of $65.23 and a 1 year high of $138.46.
ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect AveXis (AVXS) to Announce -$1.95 EPS” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/zacks-analysts-expect-avexis-avxs-to-announce-1-95-eps.html.
AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
Get a free copy of the Zacks research report on AveXis (AVXS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.